At the opening ceremony of the 2024 International Biomedical Industry Innovation Conference Beijing Forum held on October 24, the reporter learned that eight renowned international pharmaceutical enterprises such as Eli Lilly and Company, Pfizer, and Bayer, are setting up new R&D or innovation centers in Beijing, all of which are covered by Beijing's "enterprise service packages".

Six of these companies, including Eli Lilly and Company, Pfizer, Bayer, AstraZeneca, Medtronic, and HUYABIO, have chosen to site their centers in the Bio-Park in Beijing Economic-Technological Development Area (Beijing E-Town). Most of these new centers are their first ones in Beijing or even China, as part of these multinational pharmaceutical companies' footprints worldwide. According to an official of Beijing E-Town, all kinds of resources will be pooled to meet the needs in innovative development of the companies having established their presence in Beijing E-Town, providing them with high-quality services in project matchmaking and implementation, and other aspects.

According to an official of Beijing Municipal Commission of Development and Reform, Beijing regards the pharmaceutical and healthcare industries as crucial pillars of the capital's innovative development, and has introduced a series of policies in recent years to contribute to the high-quality development of innovative pharmaceutical companies. The city has been optimizing its policies for market access, business environment, and talent incentives. For instance, Beijing has accredited 149 foreign-funded R&D centers in five batches, with 40 of them in the pharmaceutical and healthcare sectors, accounting for the highest proportions among all industries.